Lack of consideration of sex and gender in COVID-19 clinical studies

Emer Brady; M. W Nielsen; Jens Peter Andersen; S. Oertelt-Prigione

doi:10.1038/s41467-021-24265-8

Lack of consideration of sex and gender in COVID-19 clinical studies

Emer Brady, M. W Nielsen, Jens Peter Andersen, S. Oertelt-Prigione^*

^*Corresponding author af dette arbejde

Institut for Statskundskab - Dansk Center for Forskningsanalyse

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avis › Tidsskriftartikel › Forskning › peer review

104 Citationer (Scopus)

Abstract

Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.

Originalsprog	Engelsk
Artikelnummer	4015
Tidsskrift	Nature Communications
Vol/bind	12
ISSN	2041-1723
DOI	https://doi.org/10.1038/s41467-021-24265-8
Status	Udgivet - 1 dec. 2021

Adgang til dokumentet

10.1038/s41467-021-24265-8Licens: CC BY

Citationsformater

@article{732a3962ac6e4714a553a349ae9067cc,

title = "Lack of consideration of sex and gender in COVID-19 clinical studies",

abstract = "Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.",

author = "Emer Brady and Nielsen, {M. W} and Andersen, {Jens Peter} and S. Oertelt-Prigione",

year = "2021",

month = dec,

day = "1",

doi = "10.1038/s41467-021-24265-8",

language = "English",

volume = "12",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Research",

}

TY - JOUR

T1 - Lack of consideration of sex and gender in COVID-19 clinical studies

AU - Brady, Emer

AU - Nielsen, M. W

AU - Andersen, Jens Peter

AU - Oertelt-Prigione, S.

PY - 2021/12/1

Y1 - 2021/12/1

N2 - Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.

AB - Sex and gender differences impact the incidence of SARS-CoV-2 infection and COVID-19 mortality. Furthermore, sex differences influence the frequency and severity of pharmacological side effects. A large number of clinical trials to develop new therapeutic approaches and vaccines for COVID-19 are ongoing. We investigated the inclusion of sex and/or gender in COVID-19 studies on ClinicalTrials.gov, collecting data for the period January 1, 2020 to January 26, 2021. Here, we show that of the 4,420 registered SARS-CoV-2/COVID-19 studies, 935 (21.2%) address sex/gender solely in the context of recruitment, 237 (5.4%) plan sex-matched or representative samples or emphasized sex/gender reporting, and only 178 (4%) explicitly report a plan to include sex/gender as an analytical variable. Just eight (17.8%) of the 45 COVID-19 related clinical trials published in scientific journals until December 15, 2020 report sex-disaggregated results or subgroup analyses.

U2 - 10.1038/s41467-021-24265-8

DO - 10.1038/s41467-021-24265-8

M3 - Journal article

C2 - 34230477

SN - 2041-1723

VL - 12

JO - Nature Communications

JF - Nature Communications

M1 - 4015

ER -

Lack of consideration of sex and gender in COVID-19 clinical studies

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater